Defining phenotypes in COPD: An aid to personalized healthcare

Molecular Diagnosis and Therapy

Volumn 18, Issue 4, 2014, Pages 381-388

  Segreti, Andrea ^a   Stirpe, Emanuele ^a   Rogliani, Paola ^a   Cazzola, Mario ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BIOLOGICAL MARKER; BRONCHODILATING AGENT; CORTICOSTEROID; MUSCARINIC RECEPTOR BLOCKING AGENT; TIOTROPIUM BROMIDE;

ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; COUGHING; DISEASE EXACERBATION; DRUG EFFICACY; DYSPNEA; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; HYPERINFLATION; LUNG EMPHYSEMA; MORBIDITY; PERSONALIZED MEDICINE; PHENOTYPE; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE; PATHOLOGY; PROCEDURES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

HUMANS; INDIVIDUALIZED MEDICINE; PHENOTYPE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84905676087     PISSN: 11771062     EISSN: 11792000     Source Type: Journal    
DOI: 10.1007/s40291-014-0100-9     Document Type: Review

References (67)

1. Miravitlles M, Calle M, Soler-Cataluna JJ. Clinical phenotypes of COPD: identification, definition and implications for guidelines. Arch Bronconeumol. 2012;48(3):86-98. doi:10.1016/j.arbres.2011.10.007.
2. Global Initiative for Chronic Obstructive Pulmonary Disease. http://www.goldcopd.org/uploads/users/files/GOLD-Report-2014.pdf.
3. Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 2004;350(10):1005-12. doi:10.1056/NEJMoa021322. (Pubitemid 38269277)
4. Hurst JR, Vestbo J, Anzueto A, Locantore N, Mullerova H, Tal-Singer R, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363(12):1128-38. doi:10.1056/NEJMoa0909883.
5. American Thoracic Society. Chronic bronchitis, asthma and pulmonary emphysema: a statement by the Committee on Diagnostic Standards for Nontuberculous Respiratory Diseases. Am Rev Respir Dis. 1962;85:762-8.
6. The definition of emphysema. Report of a National Heart, Lung, and Blood Institute, Division of Lung Diseases workshop. Am Rev Respir Dis. 1985;132(1):182-5.
7. Gibson PG, Simpson JL. The overlap syndrome of asthma and COPD: what are its features and how important is it? Thorax. 2009;64(8):728-35. doi:10.1136/thx.2008.108027.
8. Fujimoto K, Kitaguchi Y, Kubo K, Honda T. Clinical analysis of chronic obstructive pulmonary disease phenotypes classified using high-resolution computed tomography. Respirology. 2006;11(6):731-40. doi:10.1111/j.1440-1843. 2006.00930.x. (Pubitemid 44581437)
9. Kitaguchi Y, Fujimoto K, Kubo K, Honda T. Characteristics of COPD phenotypes classified according to the findings of HRCT. Respir Med. 2006;100(10):1742-52. doi:10.1016/j.rmed.2006.02.003. (Pubitemid 44283760)
10. Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest. 2000;117(5 Suppl 2):398S-401S. (Pubitemid 30314474)
11. Sapey E, Stockley RA. COPD exacerbations. 2: aetiology. Thorax. 2006;61(3):250-8. doi:10.1136/thx.2005.041822.
12. Wedzicha JA, Brill SE, Allinson JP, Donaldson GC. Mechanisms and impact of the frequent exacerbator phenotype in chronic obstructive pulmonary disease. BMC Med. 2013;11:181. doi:10.1186/1741-7015-11-181.
13. Beeh KM, Glaab T, Stowasser S, Schmidt H, Fabbri LM, Rabe KF, et al. Characterisation of exacerbation risk and exacerbator phenotypes in the POET-COPD trial. Respir Res. 2013;14:116. doi:10.1186/1465-9921-14-116.
14. Falk JA, Minai OA, Mosenifar Z. Inhaled and systemic corticosteroids in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2008;5(4):506-12. doi:10.1513/pats.200707-096ET.
15. Wedzicha JA, Decramer M, Seemungal TA. The role of bronchodilator treatment in the prevention of exacerbations of COPD. Eur Respir J. 2012;40(6):1545-54. doi:10.1183/09031936.00048912.
16. Rabe KF. Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease. Brit J Pharmacol. 2011;163(1):53-67. doi:10.1111/j.1476-5381.2011.01218.x.
17. Calverley PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, Martinez FJ. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet. 2009;374(9691):685-94. doi:10.1016/S0140- 6736(09)61255-1.
18. Wedzicha JA, Rabe KF, Martinez FJ, Bredenbroker D, Brose M, Goehring UM, et al. Efficacy of roflumilast in the COPD frequent exacerbator phenotype. Chest. 2013;143(5):1302-11. doi:10.1378/chest.12-1489.
19. Patel IS, Seemungal TA, Wilks M, Lloyd-Owen SJ, Donaldson GC, Wedzicha JA. Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations. Thorax. 2002;57(9):759-64. (Pubitemid 34984972)
20. Miravitlles M, Marin A, Monso E, Vila S, de la Roza C, Hervas R, et al. Efficacy of moxifloxacin in the treatment of bronchial colonisation in COPD. Eur Respir J. 2009;34(5):1066-71. doi:10.1183/09031936.00195608.
21. Seemungal TA, Wilkinson TM, Hurst JR, Perera WR, Sapsford RJ, Wedzicha JA. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med. 2008;178(11):1139-47. doi:10.1164/rccm.200801-145OC.
22. Albert RK, Connett J, Bailey WC, Casaburi R, Cooper JA Jr, Criner GJ, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med. 2011;365(8):689-98. doi:10.1056/NEJMoa1104623.
23. Sethi S, Jones PW, Theron MS, Miravitlles M, Rubinstein E, Wedzicha JA, et al. Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Respir Res. 2010;11:10. doi:10.1186/1465-9921-11-10.
24. Dal Negro R, Micheletto C, Tognella S, Visconti M, Turati C. Tobramycin Nebulizer Solution in severe COPD patients colonized with Pseudomonas aeruginosa: effects on bronchial inflammation. Adv Therapy. 2008;25(10):1019-30. doi:10.1007/s12325-008-0105-2.
25. Mackay AJ, Hurst JR. COPD exacerbations: causes, prevention, and treatment. Immunol Allergy Clin N Am. 2013;33(1):95-115. doi:10.1016/j.iac.2012. 10.006.
26. Cazzola M, Capuano A, Rogliani P, Matera MG. Bacterial lysates as a potentially effective approach in preventing acute exacerbation of COPD. Current Opin Pharmacol. 2012;12(3):300-8. doi:10.1016/j.coph.2012.01.019.
27. Boschetto P, Miniati M, Miotto D, Braccioni F, De Rosa E, Bononi I, et al. Predominant emphysema phenotype in chronic obstructive pulmonary. Eur Respir J. 2003;21(3):450-4. (Pubitemid 36336203)
28. Ferguson GT. Why does the lung hyperinflate? Proc Am Thorac Soc. 2006;3(2):176-9. doi:10.1513/pats.200508-094DO.
29. Gatta D, Aliprandi G, Pini L, Zanardini A, Fredi M, Tantucci C. Dynamic pulmonary hyperinflation and low grade systemic inflammation in stable COPD patients. Eur Rev Med Pharmacol Sci. 2011;15(9):1068-73.
30. Thomas M, Decramer M, O'Donnell DE. No room to breathe: the importance of lung hyperinflation in COPD. Primary Care Respir J J General Pract Airways Group. 2013;22(1):101-11. doi:10.4104/pcrj.2013.00025.
31. Tashkin DP, Cooper CB. The role of long-acting bronchodilators in the management of stable COPD. Chest. 2004;125(1):249-59. (Pubitemid 38114590)
32. Crisafulli E, Venturelli E, Biscione G, Vagheggini G, Iattoni A, Lucic S, et al. Exercise performance after standard rehabilitation in COPD patients with lung hyperinflation. Intern Emerg Med. 2011;. doi:10.1007/s11739-011-0727-z.
33. Rabe KF, Timmer W, Sagkriotis A, Viel K. Comparison of a combination of tiotropium plus formoterol to salmeterol plus fluticasone in moderate COPD. Chest. 2008;134(2):255-62. doi:10.1378/chest.07-2138.
34. Rennard SI, Calverley PM, Goehring UM, Bredenbroker D, Martinez FJ. Reduction of exacerbations by the PDE4 inhibitor roflumilast - the importance of defining different subsets of patients with COPD. Respir Res. 2011;12:18. doi:10.1186/1465-9921-12-18.
35. Lee JH, Lee YK, Kim EK, Kim TH, Huh JW, Kim WJ, et al. Responses to inhaled long-acting beta-agonist and corticosteroid according to COPD subtype. Respir Med. 2010;104(4):542-9. doi:10.1016/j.rmed.2009.10.024.
36. Criner GJ, Cordova F, Sternberg AL, Martinez FJ. The National Emphysema Treatment Trial (NETT) Part II: Lessons learned about lung volume reduction surgery. Am J Respir Crit Care Med. 2011;184(8):881-93. doi:10.1164/rccm.201103- 0455CI.
37. Ries AL, Make BJ, Reilly JJ. Pulmonary rehabilitation in emphysema. Proc Am Thorac Soc. 2008;5(4):524-9. doi:10.1513/pats.200707-093ET.
38. Zeki AA, Schivo M, Chan A, Albertson TE, Louie S. The asthma-COPD overlap syndrome: a common clinical problem in the elderly. J Allergy. 2011;2011:861926. doi:10.1155/2011/861926.
39. Beeh KM, Kornmann O, Beier J, Ksoll M, Buhl R. Clinical application of a simple questionnaire for the differentiation of asthma and chronic obstructive pulmonary disease. Respir Med. 2004;98(7):591-7. (Pubitemid 38949921)
40. Hardin M, Silverman EK, Barr RG, Hansel NN, Schroeder JD, Make BJ, et al. The clinical features of the overlap between COPD and asthma. Respir Res. 2011;12:127. doi:10.1186/1465-9921-12-127.
41. Kitaguchi Y, Komatsu Y, Fujimoto K, Hanaoka M, Kubo K. Sputum eosinophilia can predict responsiveness to inhaled corticosteroid treatment in patients with overlap syndrome of COPD and asthma. Int J Chron Obstr Pulm Dis. 2012;7:283-9. doi:10.2147/COPD.S30651.
42. Barnes PJ. Immunology of asthma and chronic obstructive pulmonary disease. Nat Rev Immunol. 2008;8(3):183-92. doi:10.1038/nri2254. (Pubitemid 351323287)
43. Brightling CE, Monteiro W, Ward R, Parker D, Morgan MD, Wardlaw AJ, et al. Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2000;356(9240):1480-5. doi:10.1016/S0140-6736(00)02872-5.
44. Siva R, Green RH, Brightling CE, Shelley M, Hargadon B, McKenna S, et al. Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial. Eur Respir J. 2007;29(5):906-13. doi:10.1183/09031936. 00146306. (Pubitemid 46711894)
45. Cazzola M, MacNee W, Martinez FJ, Rabe KF, Franciosi LG, Barnes PJ, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J. 2008;31(2):416-69. doi:10.1183/09031936.00099306.
46. Stockley RA. Biomarkers in COPD: time for a deep breath. Thorax. 2007;62(8):657-60. doi:10.1136/thx.2007.084228. (Pubitemid 47235002)
47. Kostikas K, Bakakos P, Papiris S, Stolz D, Celli BR. Systemic biomarkers in the evaluation and management of COPD patients: are we getting closer to clinical application? Current Drug Targets. 2013;14(2):177-91.
48. Cazzola M, Novelli G. Biomarkers in COPD. Pulm Pharmacol Ther. 2010;23(6):493-500. doi:10.1016/j.pupt.2010.05.001.
49. Urbani A, De Canio M, Palmieri F, Sechi S, Bini L, Castagnola M, et al. The mitochondrial Italian Human Proteome Project initiative (mt-HPP). Mol Biosystems. 2013;9(8):1984-92. doi:10.1039/c3mb70065h.
50. Snowden S, Dahlen SE, Wheelock CE. Application of metabolomics approaches to the study of respiratory diseases. Bioanalysis. 2012;4(18):2265-90. doi:10.4155/bio.12.218.
51. Neofytou E, Tzortzaki EG, Chatziantoniou A, Siafakas NM. DNA damage due to oxidative stress in chronic obstructive pulmonary disease (COPD). Int J Mol Sci. 2012;13(12):16853-64. doi:10.3390/ijms131216853.
52. Fens N, van der Schee MP, Brinkman P, Sterk PJ. Exhaled breath analysis by electronic nose in airways disease. Established issues and key questions. Clin Exp Allergy J Brit Soc Allergy Clin Immunol. 2013;43(7):705-15. doi:10.1111/cea.12052.
53. Paige M, Burdick MD, Kim S, Xu J, Lee JK, Michael Shim Y. Pilot analysis of the plasma metabolite profiles associated with emphysematous chronic obstructive pulmonary disease phenotype. Biochem Biophys Res Commun. 2011;413(4):588-93. doi:10.1016/j.bbrc.2011.09.006.
54. Bon JM, Leader JK, Weissfeld JL, Coxson HO, Zheng B, Branch RA, et al. The influence of radiographic phenotype and smoking status on peripheral blood biomarker patterns in chronic obstructive pulmonary disease. PloS one. 2009;4(8):e6865. doi:10.1371/journal.pone.0006865.
55. Boschetto P, Quintavalle S, Zeni E, Leprotti S, Potena A, Ballerin L, et al. Association between markers of emphysema and more severe chronic obstructive pulmonary disease. Thorax. 2006;61(12):1037-42. doi:10.1136/thx.2006.058321. (Pubitemid 44852020)
56. Papaioannou AI, Mazioti A, Kiropoulos T, Tsilioni I, Koutsokera A, Tanou K, et al. Systemic and airway inflammation and the presence of emphysema in patients with COPD. Respir Med. 2010;104(2):275-82. doi:10.1016/j.rmed.2009.09. 016.
57. Celli BR, Locantore N, Yates J, Tal-Singer R, Miller BE, Bakke P, et al. Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;185(10):1065-72. doi:10.1164/rccm.201110-1792OC.
58. Miravitlles M, Soriano JB, Ancochea J, Munoz L, Duran-Tauleria E, Sanchez G, et al. Characterisation of the overlap COPDasthma phenotype. Focus on physical activity and health status. Respir Med. 2013;107(7):1053-60. doi:10.1016/j.rmed.2013.03.007.
59. Bafadhel M, Saha S, Siva R, McCormick M, Monteiro W, Rugman P, et al. Sputum IL-5 concentration is associated with a sputum eosinophilia and attenuated by corticosteroid therapy in COPD. Respir Int Rev Thorac Dis. 2009;78(3):256-62. doi:10.1159/000221902.
60. Niewoehner DE. TORCH and UPLIFT: what has been learned from the COPD "mega-trials"? Copd. 2009;6(1):1-3. doi:10.1080/15412550902723984.
61. National Institute for Health and Care Excellence. http://www.nice.org. uk/nicemedia/live/13029/49397/49397.pdf.
62. Anderson D, Macnee W. Targeted treatment in COPD: a multisystem approach for a multi-system disease. Int J Chron Obstr Pulmon Dis. 2009;4:321-35.
63. Han MK, Kazerooni EA, Lynch DA, Liu LX, Murray S, Curtis JL, et al. Chronic obstructive pulmonary disease exacerbations in the COPDGene study: associated radiologic phenotypes. Radiology. 2011;261(1):274-82. doi:10.1148/radiol.11110173.
64. Cazzola M, Segreti A, Rogliani P. Comparative effectiveness of drugs for chronic obstructive pulmonary disease. Drugs Today (Barc). 2012;48(12):785-94. doi:10.1358/dot.2012.48.12.1860770.
65. Agusti A, Sobradillo P, Celli B. Addressing the complexity of chronic obstructive pulmonary disease: from phenotypes and biomarkers to scale-free networks, systems biology, and P4 medicine. Am J Respir Crit Care Med. 2011;183(9):1129-37. doi:10.1164/rccm.201009-1414PP.
66. Carolan BJ, Sutherland ER. Clinical phenotypes of chronic obstructive pulmonary disease and asthma: recent advances. J Allergy Clin Immunol. 2013;131(3):627-34; quiz 35. doi:10.1016/j.jaci.2013.01.010.
67. Miravitlles M, Soler-Cataluña JJ, Calle M, Molina J, Almagro P, Quintano JA et al. A new approach to grading and treating COPD based on clinical phenotypes: summary of the Spanish COPD guidelines (GesEPOC). Primary Care Respiratory Journal: Journal of the General Practice Airways Group. 2013;22(1):117-21, 1471-4418.